Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quantitative Temporal in Vivo Proteomics Deciphers the Transition of Virus-Driven Myeloid Cells into M2 Macrophages.
Clements DR, Murphy JP, Sterea A, Kennedy BE, Kim Y, Helson E, Almasi S, Holay N, Konda P, Paulo JA, Sharif T, Lee PW, Weekes MP, Gygi SP, Gujar S. Clements DR, et al. Among authors: holay n. J Proteome Res. 2017 Sep 1;16(9):3391-3406. doi: 10.1021/acs.jproteome.7b00425. Epub 2017 Aug 23. J Proteome Res. 2017. PMID: 28768414 Free PMC article.
First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors.
Schreiber AR, Kagihara JA, Corr BR, Davis SL, Lieu C, Kim SS, Jimeno A, Camidge DR, Williams J, Heim AM, Martin A, DeMattei JA, Holay N, Triplett TA, Eckhardt SG, Litwiler K, Winkler J, Piscopio AD, Diamond JR. Schreiber AR, et al. Among authors: holay n. Cancers (Basel). 2023 Dec 23;16(1):91. doi: 10.3390/cancers16010091. Cancers (Basel). 2023. PMID: 38201519 Free PMC article.
Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy.
Holay N, Somma A, Duchow M, Soleimani M, Capasso A, Kottapalli S, Rios J, Giri U, Diamond J, Schreiber A, Piscopio AD, Van Den Berg C, Eckhardt SG, Triplett TA. Holay N, et al. Front Immunol. 2023 Sep 6;14:1260545. doi: 10.3389/fimmu.2023.1260545. eCollection 2023. Front Immunol. 2023. PMID: 37744352 Free PMC article.
Covalent JNK Inhibitor, JNK-IN-8, Suppresses Tumor Growth in Triple-Negative Breast Cancer by Activating TFEB- and TFE3-Mediated Lysosome Biogenesis and Autophagy.
Soleimani M, Somma A, Kaoud T, Goyal R, Bustamante J, Wylie DC, Holay N, Looney A, Giri U, Triplett T, Dalby K, Kowalski J, Eckhardt SG, Van Den Berg C. Soleimani M, et al. Among authors: holay n. Mol Cancer Ther. 2022 Oct 7;21(10):1547-1560. doi: 10.1158/1535-7163.MCT-21-1044. Mol Cancer Ther. 2022. PMID: 35977156